The Center for Health + Technology (CHeT) is a clinical research organization within the University of Rochester Medical Center. #BRETT WALKER UNIVERSITY OF HAWAII TRIAL#“Validating the therapeutic benefits and safety of Celeste through a trial of this magnitude is our company’s highest priority.” “We are eagerly working with the trial team at CHeT to finalize trial preparations and begin recruitment,” Savage said. “For most people with Parkinson’s, no current therapies fully resolve their symptoms and quality of life continues to deteriorate. Karl Kieburtz, chief medical officer at PhotoPharmics. “Celeste has great promise, given the clinical results to date, its simple non-invasive approach, and its ability to be used along with all available PD therapies,” said Dr. Anyone with Parkinson’s from across the country will be able to apply, even those in remote locations as long as they have an internet connection.” Ray Dorsey, MD, lead investigator for the Celeste trial and professor of neurology at the University of Rochester Medical Center, earlier said, “A stay-at-home trial featuring a non-invasive device is perfect for our time. This pivotal, or phase 3 trial, builds on an earlier company-sponsored positive proof-of-concept clinical study which led to FDA Breakthrough device designation. These photoreceptors are critical to the circadian pathway that is damaged in Parkinson’s disease. The Celeste device delivers specialized wavelengths and intensities of light that target the activation of the melanopsin receptors in the eye. We have heard from thousands of people patiently waiting for the opportunity to experience the benefits of Celeste.” Savage added, “Fortunately, demand for non-pharmaceutical and non-invasive solutions like Celeste from people with Parkinson’s and their care partners has only increased. Once we finalize related funding details, recruitment will begin in earnest.” “We have leveraged this time to work with FDA, gather input from our clinical advisory board, and coordinate with the trial team at the University of Rochester Medical Center. “Multiple forces have aligned to make the timing for our pivotal clinical study here and now,” said Kent Savage, PhotoPharmics CEO. Brett enjoys fly-fishing, skiing, riding his motorcycle, golfing, scuba diving, camping, and UTV adventures.SALT LAKE CITY, UTAH, USA, September 16, 2022/ / - The maker of the widely anticipated Celeste ® specialized phototherapy device, PhotoPharmics, today announced plans to begin recruitment for the Celeste Light for PD trial in December. Brett loves the Utah landscape and enjoys exploring Utah’s outdoors with his three daughters. Throughout Brett’s career he has worked with adults and adolescents dealing with unresolved trauma and abuse, sexual offenses, behavioral and emotional dysregulation, addictions, mood disorders and other psychiatric disorders.īrett has specialized experience working with pornography and sexual addictions facilitating multiple therapy groups and individual therapy for sexual addicts and their spouses. This experience led Brett to obtaining a Master’s Degree in Mental Health Counseling from the University of Phoenix to become a Clinical Mental Health Counselor.īrett began working with a broad spectrum of clients that included adults, couples, adolescents and children with a variety of mental health disorders. in Criminal Justice, minoring in sociology.ĭuring his undergraduate studies, Brett worked as a direct care staff with a youth program. He graduated from Weber State University with a B.A. #BRETT WALKER UNIVERSITY OF HAWAII FREE#
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |